Nerve-Cutting surgery may boost diabetes remission after gastric bypass

NCT ID NCT07278115

First seen Jan 06, 2026

Summary

This study compares standard gastric bypass surgery to bypass plus cutting the vagus nerve (truncal vagotomy) in 40 adults with obesity and type 2 diabetes. The goal is to see if the added nerve cut improves diabetes remission rates at one year. Participants are randomly assigned and neither they nor their doctors know which procedure they received.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Diabetes Surgery

    RECRUITING

    Athens, Attica, 11527, Greece

  • Diabetes Surgery

    NOT_YET_RECRUITING

    Athens, Attica, 11527, Greece

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Roux-en-Y gastric bypass surgery with or without truncal vagotomy

What this could lead to

If it works, this could point toward a more effective surgical approach for lasting type 2 diabetes remission in people with obesity.

What could go wrong

This is a small, early-phase trial with only 40 participants. Adding vagotomy may not improve outcomes and could increase surgical risks like digestive issues or nutritional problems.

Conditions

The condition(s) this trial relates to.

hyperglycemia Insulin Resistance Obesity type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.